{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T09:21:24Z","timestamp":1772270484883,"version":"3.50.1"},"reference-count":113,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jaad.2021.02.090","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T21:01:17Z","timestamp":1618952477000},"page":"287-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["In\u00a0vitro diagnostics for the medical dermatologist. Part I: Autoimmune tests"],"prefix":"10.1016","volume":"85","author":[{"given":"Kelsey B.","family":"Nusbaum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham M.","family":"Korman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Tyler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Kaffenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Trinidad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin H.","family":"Kaffenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2021.02.090_bib1","author":"Sohn"},{"key":"10.1016\/j.jaad.2021.02.090_bib2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3389\/fimmu.2015.00412","article-title":"Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014\u20132015","volume":"6","author":"Chan","year":"2015","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.jaad.2021.02.090_bib3","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1177\/0961203316640920","article-title":"Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015","volume":"25","author":"Chan","year":"2016","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.jaad.2021.02.090_bib4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","article-title":"Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective","volume":"78","author":"Damoiseaux","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.090_bib5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10067-004-0937-0","article-title":"Utility of age, gender, ANA titer and pattern as predictors of anti-ENA and -dsDNA antibodies","volume":"23","author":"Kang","year":"2004","journal-title":"Clin Rheum"},{"key":"10.1016\/j.jaad.2021.02.090_bib6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3389\/fimmu.2018.00541","article-title":"Autoantibodies associated with connective tissue diseases: what meaning for clinicians?","volume":"9","author":"Didier","year":"2018","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.jaad.2021.02.090_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3109\/08820130903278097","article-title":"Comparative study of antinuclear antibody detection by indirect immunofluorescence and enzyme immunoassay in lupus patients","volume":"38","author":"El-Chennawi","year":"2009","journal-title":"Immunol Invesigt"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.090_bib8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/08916930310001657010","article-title":"Diagnostic accuracy of ELISA methods as an alternative screening test to indirect immunofluorescence for the detection of antinuclear antibodies. Evaluation of five commercial kits","volume":"37","author":"Tonutti","year":"2004","journal-title":"Autoimmunity"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.090_bib9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.amjmed.2012.09.014","article-title":"The clinical utility of a positive antinuclear antibody test result","volume":"126","author":"Abeles","year":"2013","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.jaad.2021.02.090_bib10","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.autrev.2017.10.006","article-title":"The inter-observer reading variability in anti-nuclear antibodies indirect (ANA) immunofluorescence test: a multicenter evaluation and a review of the literature","volume":"16","author":"Rigon","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.jaad.2021.02.090_bib11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrrheum.2017.74","article-title":"Antinuclear antibody testing\u2014Misunderstood or misbegotten?","volume":"13","author":"Pisetsky","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.090_bib12","first-page":"1054","article-title":"Evaluation of multiplexed fluorescent microsphere immunoassay for detection of autoantibodies to nuclear antigens","volume":"11","author":"Martins","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"issue":"1-2","key":"10.1016\/j.jaad.2021.02.090_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jim.2006.02.004","article-title":"Comparison of a multiplex, bead-based fluorescent assay and immunofluorescence methods for the detection of ANA and ANCA autoantibodies in human serum","volume":"311","author":"Nifli","year":"2006","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jaad.2021.02.090_bib15","series-title":"Antinuclear antibodies (ANA) Profile, 9-biomarkers, by Multiplex Immunoassay, dsDNA, RNP, Sm, SS-A, SS-B, Scl-70, Chromatin, Jo-1, Centromere B","year":"2020"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.090_bib16","doi-asserted-by":"crossref","first-page":"101462","DOI":"10.1016\/j.berh.2019.101462","article-title":"Autoantibodies in connective tissue disease","volume":"34","author":"Mulhearn","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.090_bib17","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.20980","article-title":"Relationship between anti\u2013double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus","volume":"52","author":"Linnik","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2021.02.090_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/08916930400022954","article-title":"Anti-Ro\/SSA and La\/SSB antibodies","volume":"38","author":"Franceschini","year":"2005","journal-title":"Autoimmunity"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.090_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/08916930400022707","article-title":"Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases","volume":"38","author":"Shovman","year":"2005","journal-title":"Autoimmunity"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib20","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00216-007-1243-x","article-title":"Analytical performance of the AtheNA MultiLyte ANA II assay in sera from lupus patients with multiple positive ANAs","volume":"388","author":"Biagini","year":"2007","journal-title":"Anal Bioanal Chem"},{"issue":"1-2","key":"10.1016\/j.jaad.2021.02.090_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jim.2009.10.003","article-title":"Measurement of autoantibodies using multiplex methodology in patients with systemic lupus erythematosus","volume":"352","author":"Hanly","year":"2010","journal-title":"J Immunol Methods"},{"issue":"7","key":"10.1016\/j.jaad.2021.02.090_bib22","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1191\/0961203306lu2326oa","article-title":"Autoantibody detection using multiplex technologies","volume":"15","author":"Binder","year":"2006","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.090_bib23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.autrev.2012.02.013","article-title":"Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis","volume":"12","author":"Op De Be\u00e9ck","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.jaad.2021.02.090_bib25","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.3899\/jrheum.190933","article-title":"Antinuclear antibodies (ANA) testing method variability: a survey of participants in the College of American Pathologists'(CAP) Proficiency Testing Program","volume":"47","author":"Naides","year":"2020","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.090_bib26","doi-asserted-by":"crossref","first-page":"R71","DOI":"10.1186\/ar4510","article-title":"The classification of Crithidia luciliae immunofluorescence test (CLIFT) using a novel automated system","volume":"16","author":"Buzzulini","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/acr.21930","article-title":"Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question","volume":"65","author":"Yazdany","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib28","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2015.12.002","article-title":"Choosing wisely: review and commentary on anti-nuclear antibody (ANA) testing","volume":"15","author":"Fritzler","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10067-014-2843-4","article-title":"Diagnostic value of serum complement C3 and C4 levels in Chinese patients with systemic lupus erythematosus","volume":"34","author":"Li","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.090_bib30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0377-1237(10)80118-2","article-title":"Correlation between systemic lupus erythematosus disease activity index, C3, C4 and anti-dsDNA antibodies","volume":"66","author":"Narayanan","year":"2010","journal-title":"Med J Armed Forces India"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib31","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12016-012-8320-4","article-title":"Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up?","volume":"43","author":"Cohen Tervaert","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.090_bib32","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1309\/AJCP4Y8ADMKOSCXV","article-title":"Diagnostic value of distinguishing and reporting different perinuclear ANCA (P-ANCA) immunofluorescence patterns: a prospective study","volume":"140","author":"Perel","year":"2013","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"10.1016\/j.jaad.2021.02.090_bib33","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1136\/jcp.51.8.568","article-title":"A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies","volume":"51","author":"Savige","year":"1998","journal-title":"J Clin Pathol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.090_bib34","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/annrheumdis-2016-209507","article-title":"Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays","volume":"76","author":"Damoiseaux","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jaad.2021.02.090_bib35","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrrheum.2017.140","article-title":"Position paper: revised 2017 International consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis","volume":"13","author":"Bossuyt","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.090_bib36","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3899\/jrheum.140941","article-title":"Myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCA) and proteinase 3-ANCA without immunofluorescent ANCA found by routine clinical testing","volume":"42","author":"Rao","year":"2015","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib37","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s12016-017-8616-5","article-title":"Cutaneous manifestations of ANCA-associated small vessels vasculitis","volume":"53","author":"Marzano","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.090_bib38","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s10157-012-0736-x","article-title":"Skin involvement in ANCA-associated vasculitis","volume":"17","author":"Chen","year":"2013","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.090_bib39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","article-title":"Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis\u2014a meta-analysis","volume":"51","author":"Tomasson","year":"2012","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib40","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1681\/ASN.2013111233","article-title":"ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease","volume":"26","author":"Kemna","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib41","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1523-1755.2003.00821.x","article-title":"Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis","volume":"63","author":"Han","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.jaad.2021.02.090_bib42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.rmed.2016.07.009","article-title":"Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome","volume":"118","author":"Zamora","year":"2016","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1297-319X(03)00012-5","article-title":"Antisynthetase syndrome","volume":"70","author":"Imbert-Masseau","year":"2003","journal-title":"Joint Bone Spine"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.090_bib44","first-page":"1012","article-title":"Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis","volume":"34","author":"Matsushita","year":"2007","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.02.090_bib45","doi-asserted-by":"crossref","first-page":"909","DOI":"10.6061\/clinics\/2013(07)04","article-title":"Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis","volume":"68","author":"Cruellas","year":"2013","journal-title":"Clinics (Sao Paulo)"},{"issue":"7","key":"10.1016\/j.jaad.2021.02.090_bib46","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/art.1780280711","article-title":"The association between Mi-2 antibodies and dermatomyositis","volume":"28","author":"Targoff","year":"1985","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.090_bib47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.090_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"issue":"19","key":"10.1016\/j.jaad.2021.02.090_bib49","doi-asserted-by":"crossref","first-page":"e1768","DOI":"10.1212\/WNL.0000000000008443","article-title":"More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.090_bib50","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.clindermatol.2018.04.008","article-title":"Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis","volume":"36","author":"Tartar","year":"2018","journal-title":"Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.090_bib51","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/bjd.17098","article-title":"Autoantibody to transcriptional intermediary factor-1\u03b2 as a myositis-specific antibody: clinical correlation with clinically amyopathic\u00a0dermatomyositis or dermatomyositis with mild myopathy","volume":"180","author":"Ueda-Hayakawa","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib52","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis","volume":"72","author":"Fiorentino","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.090_bib53","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/1346-8138.15128","article-title":"Anti-transcriptional intermediary factor 1-\u03b3 antibody as a biomarker in patients with dermatomyositis","volume":"47","author":"Shimizu","year":"2020","journal-title":"J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2021.02.090_bib54","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.090_bib55","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.090_bib56","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaad.2017.12.010","article-title":"Anti-melanoma differentiation\u2013associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features","volume":"78","author":"Kurtzman","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.090_bib57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.090_bib58","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.02.090_bib59","doi-asserted-by":"crossref","first-page":"160","DOI":"10.21037\/atm.2017.03.94","article-title":"MDA5 autoantibody\u2013Another indicator of clinical diversity in dermatomyositis","volume":"5","author":"Sontheimer","year":"2017","journal-title":"Ann Transl Med"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.090_bib60","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/acr.22498","article-title":"Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation\u2013associated gene 5 antibodies and interstitial lung disease","volume":"67","author":"Narang","year":"2015","journal-title":"Arthritis Care Res"},{"issue":"11","key":"10.1016\/j.jaad.2021.02.090_bib61","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/acr.23188","article-title":"Dermatomyositis patients with anti-nuclear matrix protein-2 autoantibodies have more edema, more severe muscle disease, and increased malignancy risk","volume":"69","author":"Albayda","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.090_bib62","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/rheumatology\/kex516","article-title":"Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis","volume":"57","author":"Aouizerate","year":"2018","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.jaad.2021.02.090_bib63","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","article-title":"Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset","volume":"53","author":"Tansley","year":"2014","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.jaad.2021.02.090_bib64","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.autrev.2014.08.011","article-title":"Four dermatomyositis-specific autoantibodies-anti-TIF1\u03b3, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort","volume":"13","author":"Bodoki","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.jaad.2021.02.090_bib65","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/ard.2008.097162","article-title":"Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis","volume":"68","author":"Betteridge","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.090_bib66","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41598-017-00240-6","article-title":"Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts","volume":"7","author":"Ge","year":"2017","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.jaad.2021.02.090_bib67","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1136\/annrheumdis-2017-212709","article-title":"Response to: '2017 EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?' by Malaviya","volume":"77","author":"Lundberg","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jaad.2021.02.090_bib68","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1136\/annrheumdis-2017-212701","article-title":"2017 EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?","volume":"77","author":"Malaviya","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.jaad.2021.02.090_bib69","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.090_bib70","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jaad.2019.05.105","article-title":"Dermatomyositis: diagnosis and treatment","volume":"82","author":"Waldman","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.090_bib71","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/1744666X.2019.1699059","article-title":"Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis","volume":"16","author":"Gono","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.090_bib72","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00403-016-1631-1","article-title":"Evaluation of ELISA testing for BP180 and BP230 as a diagnostic modality for bullous pemphigoid: a clinical experience","volume":"308","author":"Keller","year":"2016","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.090_bib73","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jaad.2013.07.009","article-title":"Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid","volume":"69","author":"S\u00e1rdy","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib74","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0923-1811(02)00109-3","article-title":"BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid","volume":"30","author":"Kobayashi","year":"2002","journal-title":"J Dermatol Sci"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.090_bib75","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/1523-1747.ep12338088","article-title":"A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid","volume":"109","author":"Zillikens","year":"1997","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.090_bib76","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5021\/ad.2012.24.1.45","article-title":"Usefulness of enzyme-linked immunosorbent assay using recombinant BP180 and BP230 for serodiagnosis and monitoring disease activity of bullous pemphigoid","volume":"24","author":"Lee","year":"2012","journal-title":"Ann Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.02.090_bib77","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1600-0625.2007.00592.x","article-title":"Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies","volume":"16","author":"Sitaru","year":"2007","journal-title":"Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.090_bib78","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.0022-202X.2004.22603.x","article-title":"BP230-and BP180-specific auto-antibodies in bullous pemphigoid","volume":"122","author":"Thoma-Uszynski","year":"2004","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib79","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archdermatol.2011.23","article-title":"Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients","volume":"147","author":"Charneux","year":"2011","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.090_bib80","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jdermsci.2005.11.002","article-title":"Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid","volume":"41","author":"Yoshida","year":"2006","journal-title":"J Dermatol Sci"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.090_bib81","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jaad.2019.03.062","article-title":"Circulating bullous pemphigoid autoantibodies in the setting of negative direct immunofluorescence findings for bullous pemphigoid: a single-center retrospective review","volume":"81","author":"Wang","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib82","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jaad.2018.06.006","article-title":"Circulating bullous pemphigoid 180 autoantibody can be detected in a wide spectrum of patients with other dermatologic conditions: a cross-sectional study","volume":"80","author":"Liu","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib83","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4103\/2229-5178.156386","article-title":"Role of direct immunofluorescence in dermatological disorders","volume":"6","author":"Mysorekar","year":"2015","journal-title":"Indian Dermatol Online J"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.090_bib84","doi-asserted-by":"crossref","first-page":"119","DOI":"10.47102\/annals-acadmedsg.V44N4p119","article-title":"Anti-BP180 NC16A IgG titres as an indicator of disease activity and outcome in Asian patients with bullous pemphigoid","volume":"44","author":"Cai","year":"2015","journal-title":"Ann Acad Med Singap"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.090_bib85","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archderm.136.2.174","article-title":"Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid","volume":"136","author":"Schmidt","year":"2000","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib86","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1046\/j.1365-2230.2000.00624.x","article-title":"Diagnosis of pemphigus by ELISA: a critical evaluation of two ELISAs for the detection of antibodies to the major pemphigus antigens, desmoglein 1 and 3","volume":"25","author":"Harman","year":"2000","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.090_bib87","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1600-0625.2010.01069.x","article-title":"Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients","volume":"19","author":"Schmidt","year":"2010","journal-title":"Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.090_bib88","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-2133.1999.02752.x","article-title":"Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus","volume":"140","author":"Amagai","year":"1999","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.090_bib89","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.4049\/jimmunol.159.4.2010","article-title":"Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins","volume":"159","author":"Ishii","year":"1997","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.090_bib90","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archdermatol.2009.9","article-title":"ELISA testing of anti\u2013desmoglein 1 and 3 antibodies in the management of pemphigus","volume":"145","author":"Abasq","year":"2009","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.090_bib91","doi-asserted-by":"crossref","first-page":"364","DOI":"10.4103\/0019-5154.135488","article-title":"A cross-sectional study of direct immunofluorescence in the diagnosis of immunobullous dermatoses","volume":"59","author":"Buch","year":"2014","journal-title":"Indian J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.090_bib92","first-page":"E287","article-title":"Sensitivity of\u00a0direct\u00a0immunofluorescence in oral diseases. Study of 125\u00a0cases","volume":"13","author":"Sano","year":"2008","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.090_bib93","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2133.2001.04132.x","article-title":"The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels","volume":"144","author":"Harman","year":"2001","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.090_bib94","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjd.12011","article-title":"Diagnosis and disease severity assessment of epidermolysis bullosa acquisita by ELISA for anti-type VII collagen autoantibodies: an Italian multicentre study","volume":"168","author":"Marzano","year":"2013","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib95","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jdermsci.2011.03.003","article-title":"Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients","volume":"62","author":"Saleh","year":"2011","journal-title":"J Dermatol Sci"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.090_bib96","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1111\/j.1468-3083.2012.04617.x","article-title":"Serum levels of anti-type VII collagen antibodies detected by enzyme-linked immunosorbent assay in patients with epidermolysis bullosa acquisita are correlated with the severity of skin lesions","volume":"27","author":"Kim","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib97","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.jaad.2011.12.032","article-title":"Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita","volume":"68","author":"Komorowski","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.02.090_bib98","first-page":"1077","article-title":"Diagnosis of autoimmune bullous diseases","volume":"16","author":"van Beek","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1-2","key":"10.1016\/j.jaad.2021.02.090_bib99","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12016-007-0027-6","article-title":"Autoimmunity to type VII collagen: epidermolysis bullosa acquisita","volume":"33","author":"Woodley","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5 Pt 2","key":"10.1016\/j.jaad.2021.02.090_bib100","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0190-9622(98)70472-4","article-title":"Bullous systemic lupus erythematosus: detection of antibodies against noncollagenous domain of type VII collagen","volume":"38","author":"Shirahama","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2021.02.090_bib101","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/CCID.S69127","article-title":"The diagnosis and treatment of dermatitis herpetiformis","volume":"8","author":"Antiga","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.090_bib102","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jaad.2010.09.776","article-title":"Dermatitis herpetiformis: part II. Diagnosis, management, and prognosis","volume":"64","author":"Bolotin","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.090_bib103","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaad.2008.12.037","article-title":"Autoantibodies against epidermal transglutaminase are a sensitive diagnostic marker in patients with dermatitis herpetiformis on a normal or gluten-free diet","volume":"61","author":"Rose","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.090_bib104","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/sj.jid.5701041","article-title":"Transglutaminase autoantibodies in dermatitis herpetiformis and celiac sprue","volume":"128","author":"Marietta","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib105","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.clindermatol.2007.10.018","article-title":"Skin manifestations of inflammatory bowel disease","volume":"26","author":"Timani","year":"2008","journal-title":"Clin Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.090_bib106","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12016-017-8617-4","article-title":"Skin manifestations of inflammatory bowel disease","volume":"53","author":"Greuter","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.090_bib107","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2036.2005.02632.x","article-title":"Variation in practice of ileal intubation among diverse endoscopy settings: results from a National endoscopic database","volume":"22","author":"Harewood","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.jaad.2021.02.090_bib108","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1111\/j.1572-0241.2003.07673.x","article-title":"Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment","volume":"98","author":"Teml","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.090_bib109","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12016-012-8344-9","article-title":"Anti-Saccharomyces cerevisiae autoantibodies in autoimmune diseases: from bread baking to autoimmunity","volume":"45","author":"Rinaldi","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.090_bib110","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/gast.2001.22546","article-title":"Comparative study of ASCA (Anti\u2013Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease","volume":"120","author":"Vermeire","year":"2001","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.090_bib111","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00384-003-0557-1","article-title":"Optimising the diagnostic value of anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn's disease","volume":"19","author":"Klebl","year":"2004","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.090_bib112","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1111\/j.1572-0241.2006.00840.x","article-title":"Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease","volume":"101","author":"Reese","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.090_bib113","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/MIB.0b013e318280b19e","article-title":"Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patients","volume":"19","author":"Plevy","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2021.02.090_bib114","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/CEG.S97701","article-title":"Fecal calprotectin: a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome","volume":"9","author":"von Arnim","year":"2016","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.jaad.2021.02.090_bib115","doi-asserted-by":"crossref","first-page":"c3369","DOI":"10.1136\/bmj.c3369","article-title":"Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis","volume":"341","author":"Van Rheenen","year":"2010","journal-title":"BMJ"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221006769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221006769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:57:29Z","timestamp":1759273049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962221006769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":113,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0190962221006769"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.02.090","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In\u00a0vitro diagnostics for the medical dermatologist. Part I: Autoimmune tests","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.02.090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(21)01954-X","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}